Collegium Pharma (COLL) Tops Q2 EPS by 20c; Offers Guidance

Collegium Pharma (NASDAQ: COLL) reported Q2 EPS of $1.92, $0.20 better than the analyst estimate of $1.72. Revenue for the quarter came in at $199.87 million versus the consensus estimate of $201.41 million.

FY2026 Outlook-

Revenue between $825 million to $855 million versus the consensus $869.9 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.

You May Also Be Interested In

• Kepler Cheuvreux Downgrades Thyssenkrupp Nucera AG (NCH2:GR) to Hold
• MongoDB (MDB) Tops Q2 EPS by 29c, Beats on Revenue; Offers FY37 Guidance
• Knight Transportation (KNX) Reiterated at Market Outperform by Citizens